Harbour BioMed gets rights to two HanAll compounds in Greater China
HanAll Biopharma Co. Ltd. (majority owned by Daewoong) licensed Harbour BioMed rights to develop, manufacture, and commercialize two programs in Greater China, including Hong Kong, Macau, and Taiwan.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.